SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

EKSO BIONICS HOLDING (OTCBB:EKSO) earned some traction after reporting the appointment of Amy Wendell as its Board of Directors. Wendell is a former Senior Vice President, Strategy and Business Development of Covedien.

Welcomed Wendell as Board Of Director

Wendell’s role at Covidien was majorly centered on forming acquisition strategy. During her tenure, Wendell played a critical role in solidifying Covidien’s portfolio through the acquisition of over 100 companies across several healthcare sectors.

Welcoming on the board, CEO and Co-founder, Nathan Harding said that Wendell’s experience will help EKSO BIONICS HOLDING (OTCBB:EKSO) in an exceptional way. Harding said that Wendell brings with her the valuable inputs on growth strategies and a rich operational and product knowledge. Meanwhile, Wendell said that she is excited to associate with a medical device company, which aims to make a difference in peoples’ lives. She showed the commitment of helping the company achieve new milestones and extend its presence into new markets.

Cash reserve is comforting

Among the penny stocks, EKSO BIONICS HOLDING (OTCBB:EKSO) has so far been able to report a fair financial position. As per its recent annual report, released in March, the company recorded $25.2 million cash and $33.4 million in total current assets. The current liabilities of the company stood at $6.6 million while it incurred a loss of $16.8 million from operations. The annual revenue and net loss of the company were $5.3 million and $33 million respectively.

As evident, EKSO BIONICS HOLDING (OTCBB:EKSO) has tremendously improved its cash position, which is built through the exercise of warrants late last year. Despite bigger losses, the company has a margin to manage the operations through the second quarter of 2016, which is quite comforting.

The stock of EKSO BIONICS HOLDING (OTCBB:EKSO) ended 3.65% higher at $1.99 in the previous trading session, when the average number of shares traded were 931,232.

SHARE
Previous articleThinspace Technology Inc (OTCMKTS:THNS) Gets Boost From Its Featured Interview On Big Biz
Next articleGOLDEN GRAIL TECHNOLOGY CORP (OTCMKTS:GOGY) Launches Second Successful eCommerce Venture
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg, Equities.com, Hacked.com, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.